Shots:

• Prothena presents new data for PRX012 (anti-amyloid beta (Aβ) Ab) and the company’s dual Aβ-tau vaccine program being developed for the prevention and treatment of AD
• The preclinical data of PRX012 (SC) highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS. PRX012 showed higher potency & biologic activity than aducanumab with its expected IND to be filed in Q1’22
• The dual Aβ-tau vaccines generate Abs that neutralize and clear pathogenic Aβ and block pathogenic tau interaction

 ­ Ref: Prothena | Image: Boston University